learndrugs
Nervous

Huntington’s Disease

Huntington disease (HD) Verified · Sep 2026

NINDS: "Huntington's disease (HD) is an inherited disorder that causes nerve cells (neurons) in parts of the brain to slowly break down and die. The disease affects areas of the brain that control voluntary (intentional) movement." StatPearls: it "is characterized by the clinical triad of involuntary choreiform movements with cognitive and behavioral disturbances."

HD is autosomal dominant: one altered copy of the gene is enough, and "The chance that each offspring of a patient with Huntington disease will develop the disease is 50%." Mood and thinking often change before the movements do. The nurse watches three things closely: swallowing (choking, aspiration, weight loss), falls and injury, and suicide risk — especially when a VMAT2 inhibitor is started. Suicidal thoughts in a patient with HD are evaluated immediately.

What’s going wrong in the body

The normal physiology, where it fails, and why the body’s compensation backfires.

01 An autosomal dominant repeat expansion

"HD is caused by a change in the gene that makes the protein huntingtin (HTT). This change causes a section of DNA called CAG to repeat itself many more times than normal, causing production of an abnormal version of huntingtin that damages brain cells" (NINDS). The gene sits on chromosome 4.

Inheritance. "When a parent has HD, each child has a 50% chance of inheriting the genetic variant. If a child does not inherit the variant, they won’t develop the disease and can’t pass it on to future generations" (NINDS). MedlinePlus Genetics: one copy of the altered gene in each cell "is sufficient to cause the disorder."

Repeat length matters (figures differ slightly by source). NINDS: "Most people have fewer than 27 CAG repeats in their HD gene, so they aren’t at risk for the disease." "People who have CAG repeats in the middle range (27 to 35) aren’t likely to develop the disease, but they could still pass it on to future generations." "People with HD may have 36 or more CAG repeats." MedlinePlus Genetics: "People with 36 to 39 CAG repeats may or may not develop the signs and symptoms of Huntington's disease, while people with 40 or more repeats almost always develop the disorder."

Anticipation. As the gene passes down a family, the repeat often grows, and "A larger number of repeats is usually associated with an earlier onset of signs and symptoms" (MedlinePlus Genetics). StatPearls: "In Huntington disease, the anticipation phenomenon is seen mainly in the paternal line of inheritance, which arises due to the instability of the CAG repeats during spermatogenesis." A negative family history does not rule HD out — the parent may have died early, had late-onset disease or never been diagnosed.

Autosomal dominant inheritance with a repeat-length gradient: each child has a 50% chance, and longer repeats bring earlier onset.

02 Toxic huntingtin and the striatum

"An increase in the size of the CAG segment leads to the production of an abnormally long version of the huntingtin protein. The elongated protein is cut into smaller, toxic fragments that bind together and accumulate in neurons, disrupting the normal functions of these cells" (MedlinePlus Genetics).

The striatum fails first. "The primary feature is the degeneration of neurons of the striatum, ie, the putamen and the caudate." Most striatal projection neurons are GABAergic, and "Throughout Huntington disease, over 90% of these GABAergic neurons degenerate" (StatPearls). The typical MRI finding is caudate atrophy with a "boxcar appearance" (StatPearls, Chorea).

Why the movements happen. "Striatal modulation is mainly inhibitory through GABAergic innervation. Consequently, any striatal lesion can disrupt this inhibitory mechanism, resulting in hyperkinetic movement disorders such as chorea or choreoathetosis." These disorders "are believed to result from increased phasic dopaminergic signaling in the striatum" (StatPearls, Chorea). That is why drugs that deplete dopamine (VMAT2 inhibitors) reduce chorea.

Beyond movement. Neurodegeneration also occurs "throughout the cerebral cortex," and "The involvement of the cingulate gyrus is associated with emotion and mood disturbances" (StatPearls). Brain changes start early: "measurable brain and behavioral changes can be detected up to 15 years before an HD diagnosis" (NINDS).

Toxic huntingtin fragments kill striatal GABAergic neurons (chorea, later rigidity) and cortical neurons (cognitive and psychiatric changes).

03 The triad over time — and what ends life

"The signs and symptoms classically consist of the triad of motor, cognitive, and psychiatric disturbances" (StatPearls). Motor signs are not always first: "Behavioral and psychiatric symptoms are present very early in the disease, often even before the onset of motor manifestations" (StatPearls), and motor symptoms "are frequently preceded by cognitive and behavioral symptoms" (EHDN guideline).

Onset and course (attributed). "Huntington disease commonly affects patients between the ages of 30 to 50" (StatPearls); NHS says symptoms "usually start in adults aged between 30 and 50, but it can happen at any age." Adults "usually live about 15 to 20 years after signs and symptoms begin" (MedlinePlus Genetics). Early chorea is hyperkinetic; "In later stages, however, hypokinesia with bradykinesia and dystonia may predominate" (StatPearls). Juvenile HD (onset before age 20, StatPearls) is rare (NINDS).

Swallowing, weight and the lungs. "Dysarthria and dysphagia develop during the course of the disease, which could lead to aspiration in patients, with pneumonia being a common cause of death" (StatPearls). The EHDN guideline adds that swallowing disorders can become "a major problem in later stages by inducing repeated choking and leading to secondary bronchopulmonary infections or even cardiac arrest." Weight loss "might occur despite normal, or even high calorie intake, due to a significant energy expenditure in HD patients" (EHDN).

Causes of death. "Aspiration pneumonia is the most frequent cause of death, which is followed by suicide" (StatPearls). "Approximately 25% of the patients attempt suicide" (StatPearls).

HD moves from presymptomatic to prodromal to manifest disease; swallowing failure and suicide are the leading causes of death (StatPearls).

Causes & risk factors

Modifiable factors are teaching targets — the patient can act on them.

A parent with HD — autosomal dominant; each child has a 50% chance of inheriting the variant (NINDS) CAG repeat length — 36 or more in people with HD (NINDS); 40 or more almost always causes the disorder (MedlinePlus Genetics) Paternal transmission — anticipation (repeat growth, earlier onset) is seen mainly in the paternal line (StatPearls) Intermediate alleles (27–35 repeats) in a parent — the carrier is unlikely to develop HD, but the repeat may expand into the disease range in children (NINDS, StatPearls)

Signs & symptoms

Each finding tied to the mechanism that produces it — and the triage it calls for.

Chorea — uncontrollable dance-like movements of the fingers, feet, face or torso early Expected
Why: NINDS: these movements "can get worse over time or when the person is nervous or distracted." StatPearls: chorea "initially begins in the distal extremities" and spreads to proximal and axial muscles. EHDN: "Drug treatment should be considered if chorea causes the patient distress or discomfort" — mild chorea that does not bother the patient may need no drug.
Irritability, apathy, depression, mood swings, pulling away from family — often before chorea early Hold & notify
Why: StatPearls: "The irritability is often severe and leads to outbursts of anger and aggression," and "The most common feature of the disease is apathy." Behavioral symptoms often come "even before the onset of motor manifestations." Report new or worsening depression promptly.
Suicidal thoughts or talk of suicide Report immediately
Why: VMAT2 labels: "Patients with HD who express suicidal ideation should be evaluated immediately." About 25% of patients attempt suicide, and suicide is the second cause of death (StatPearls). EHDN: suicide risk should be assessed "irrespective of the stage."
Executive dysfunction — trouble organizing, planning, multitasking; lack of insight early
Why: StatPearls: cognitive changes "are more prominent for executive functions," and progress to a subcortical dementia. Patients often lack insight, so "family members become a crucial source of information and should be involved in decision-making and assessment."
Slurred speech, difficulty swallowing, coughing at meals, weight loss late Hold & notify
Why: NINDS: "Weight loss due to problems with eating and swallowing, which may lead to choking and lung infections." EHDN: swallowing should be reassessed regularly, with speech-and-language referral "as soon as the disorders appear."
Choking during a meal — airway obstruction Report immediately
Why: EHDN: dysphagia can cause "repeated choking" and "even cardiac arrest." Chorea at mealtimes needs protective measures "to avoid traumatic injury or chokes."
Clumsiness, balance problems, trouble walking, falls Hold & notify
Why: NINDS: "Trouble walking, which may increase the chances of falling." StatPearls: large-amplitude chorea "can also lead to fractures and head trauma."
Rigidity, slowness, dystonia, contractures (late disease) late
Why: StatPearls: "In later stages, however, hypokinesia with bradykinesia and dystonia may predominate," leading some patients to become bedridden.

Diagnostics

Test In this disorder Normal
Genetic test — CAG repeat count in the HTT gene StatPearls: "The gold standard for evaluation is genetic testing, which is targeted testing of the CAG repeat size." NINDS: "The most accurate way to test for HD is to count the number of CAG repeats in a person’s HTT gene using DNA from a blood sample." 36 or more repeats in people with HD (NINDS); 40 or more almost always causes the disorder (MedlinePlus Genetics) NINDS · MedlinePlus Genetics —
Predictive (presymptomatic) testing — with genetic counseling NHS: "It's your choice whether you have the test. As Huntington's disease cannot currently be prevented, some people choose not to get tested, especially if they do not have symptoms." "Your GP can arrange an appointment with a specialist called a genetic counsellor, who can help you decide." StatPearls: testing helps people "make informed decisions concerning the caregiver, finances, and reproduction," and "The optimal time to determine the genetic risk as well as discuss prenatal testing is before pregnancy." A personal choice; usually offered at 18 or older (NHS) NHS —
MRI or CT StatPearls (Chorea): "The classical MRI finding in Huntington disease is caudate atrophy, which results in a boxcar appearance." NINDS: "people with early HD may have normal scans." Caudate atrophy ("boxcar appearance"); early HD may have normal scans —
Psychiatric evaluation, including suicidality StatPearls (Chorea): evaluation includes "a psychiatric evaluation to assess deficits in cognitive, behavioral, and functional areas. Inquiry about suicidality is crucial." Cognitive, behavioral and functional deficits documented —
Swallowing and nutrition screening EHDN (Grade C): "Regular assessment of swallowing disorders should be provided throughout the progression of the disease." "Screening tools for malnutrition [e.g., malnutrition Universal Screening Tool (MUST)] are recommended." EHDN recommends intervention "when unintended weight loss is higher than 10% within last 3–6 months." Serial weight and BMI; swallowing assessment EHDN 2019 —

Complications

Black-box warning — most severe: ■ [XEN][AUS][ING] VMAT2 inhibitors — depression and suicidality (boxed warning) Report immediately
XENAZINE: "XENAZINE can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease." INGREZZA: "VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior in patients with Huntington’s disease."
"Close observation of patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior should accompany therapy." "Patients, their caregivers, and families should be informed of the risk of depression and suicidality and should be instructed to report behaviors of concern promptly to the treating physician" (XENAZINE). XENAZINE and AUSTEDO are contraindicated in patients who are actively suicidal or have untreated or inadequately treated depression.
Warning: Aspiration pneumonia — the most frequent cause of death Hold & notify
"Aspiration pneumonia is the most frequent cause of death, which is followed by suicide" (StatPearls). Swallowing disorders can lead to "secondary bronchopulmonary infections or even cardiac arrest" (EHDN).
XENAZINE label: "drugs that reduce dopaminergic transmission have been associated with esophageal dysmotility and dysphagia. Dysphagia may be associated with aspiration pneumonia." EHDN: "Reduced lung function and respiratory muscle strength are not only associated with end stage disease but occur much earlier."
Warning: [XEN][ING] Neuroleptic malignant syndrome Report immediately
"A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with XENAZINE and other drugs that reduce dopaminergic transmission." "Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability."
Management begins with "immediate discontinuation of XENAZINE." INGREZZA: "Advise patients to contact a healthcare provider or report to the emergency room if they experience signs or symptoms of NMS."
Warning: [XEN][AUS][ING] QT prolongation — fainting or palpitations on AUSTEDO or INGREZZA: call immediately Report immediately
XENAZINE "should be avoided in combination with other drugs that are known to prolong QTc, including antipsychotic medications (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone)," and in patients with congenital long QT syndrome or a history of arrhythmias.
AUSTEDO and INGREZZA: "Inform patients to consult their physician immediately if they feel faint, lose consciousness, or have heart palpitations."
Caution: [XEN][AUS] Parkinsonism, akathisia and sedation Hold & notify
"Drug-induced parkinsonism has the potential to cause more functional disability than untreated chorea for some patients with Huntington’s disease." "Sedation is the most common dose-limiting adverse reaction of XENAZINE."
XENAZINE: "Sedation, akathisia, parkinsonism, depression, and difficulty swallowing may occur. Such symptoms should be promptly reported to the physician." Because rigidity is also part of HD, "it may be difficult to distinguish between this drug-induced adverse reaction and progression of the underlying disease process."
Caution: Falls and injury Hold & notify
"Chorea with larger amplitude can lead to injury and poor positioning. It can also lead to fractures and head trauma" (StatPearls). "Localized trauma or rhabdomyolysis may result from severe involuntary movements" (StatPearls, Chorea).

Medications for this condition

Why each class is prescribed here — every card links to its full pharmacology page.

Beyond medications

  • VMAT2 inhibitors for chorea (no class page — prose only). Tetrabenazine, deutetrabenazine and valbenazine "decrease dopamine's bioavailability in the synapses" (StatPearls). EHDN (2019): "Tetrabenazine is one of the first-line treatments for this symptom (Grade A)" — "unless the patient suffers from not well-managed depression or suicidal thoughts." AUSTEDO tablets are swallowed whole — not chewed, crushed or broken; INGREZZA SPRINKLE capsules may be opened over soft food. Tetrabenazine above a set daily dose requires CYP2D6 genotyping (XENAZINE label). No doses here.
  • No cure, no approved disease-modifying drug. "There is no treatment that can stop or reverse HD, but some of the symptoms can be treated" (NINDS). "No pharmacological agent is effective or indicated for cognitive impairment in Huntington disease" (StatPearls).
  • Team care (NHS): antidepressants and talking therapies such as CBT, medicines for chorea, "physiotherapy to help with movement problems," "occupational therapy to help with daily activities," and "speech and language therapy." NINDS adds mental health professionals and genetic counselors.
  • Nutrition (EHDN, Grade C). "Good nutritional care is a fundamental element of the management of HD." "A high Body Mass Index (BMI) within normal values should be maintained if possible," and when weight is lost, "high-calorie and high-protein food supplements should be prescribed under instruction and monitored by a dietician/nutritionist."
  • Swallowing (EHDN). "Provision of information and advice on safe swallowing procedures, on posture and positional changes can help to avoid aspirations." A PEG "should be anticipated and discussed with relatives and patients still able to understand the benefits and burdens of the methods."
  • Falls prevention (EHDN). Physiotherapy (Grade B), falls-prevention, gait and balance programs (Grade C), and a four-wheeled walker (Grade B) "to improve stability and reduce fall risk." "Maintaining physical activity and low impact exercises is recommended."
  • Irritability (EHDN). "Before initiating pharmacological treatment, possible environmental causes for the patient's frustration and irritability should be explored." "A structured plan with a regular routine in a calming environment is desirable."
  • Supportive care (StatPearls): attention to diet, nursing and special equipment; "smoking and alcohol use is discouraged"; emotional support and counseling for patients and families.

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Assessment
Ask directly about suicidal thoughts at every stage — especially at diagnosis, when the disease starts to affect daily life, and when a VMAT2 inhibitor is started.
Why: EHDN: suicide risk "should be assessed in HD irrespective of the stage, being particularly vigilant at the time of diagnosis and when the disease starts to impact on day-to-day life." About 25% attempt suicide (StatPearls).
Watch meals for coughing and choking; weigh the patient regularly and screen nutrition.
Why: Dysphagia leads to aspiration, and aspiration pneumonia is the most frequent cause of death (StatPearls). Weight loss can occur "despite normal, or even high calorie intake" (EHDN).
Assess gait, balance and fall risk, and look for bruises or injuries from chorea.
Why: Chorea "can also lead to fractures and head trauma" (StatPearls).
Gather history from family members as well as the patient.
Why: StatPearls: many patients lack insight into their symptoms, so "family members become a crucial source of information."
On a VMAT2 inhibitor, check for sadness, withdrawal, insomnia, irritability, akathisia, agitation, parkinsonism, sedation and new swallowing trouble; check standing vital signs if the patient is prone to hypotension.
Why: XENAZINE label: these symptoms are reported "promptly to the patient’s physician"; "Monitoring of vital signs on standing should be considered in patients who are vulnerable to hypotension."
Interventions
Before a VMAT2 inhibitor dose, hold and notify if the patient voices suicidal thoughts or shows new or untreated depression; arrange immediate evaluation for suicidal ideation.
Why: "Patients with HD who express suicidal ideation should be evaluated immediately." XENAZINE and AUSTEDO are contraindicated in active suicidality or untreated depression.
Set up safe meals: upright posture, the swallowing strategies taught by speech therapy, and protection from chorea at mealtimes; refer to speech therapy as soon as swallowing problems appear.
Why: EHDN: advice on "safe swallowing procedures, on posture and positional changes can help to avoid aspirations"; referral "as soon as the disorders appear (Grade C)."
Provide high-calorie, high-protein supplements and snacks as ordered by the dietitian; never restrict intake to control weight.
Why: EHDN (Grade C): keep BMI in the high-normal range; supplements are "monitored by a dietician/nutritionist."
Use fall precautions: physiotherapy and a four-wheeled walker if recommended, and protective positioning where chorea causes injury.
Why: EHDN recommends falls-prevention programs and assistive devices "to improve stability and reduce fall risk."
For irritability, keep a calm, predictable routine, look for environmental triggers, and use diversion rather than confrontation.
Why: EHDN: explore environmental causes first; "A structured plan with a regular routine in a calming environment is desirable."
Check the formulation before crushing or opening any VMAT2 inhibitor for a patient with dysphagia.
Why: AUSTEDO: swallow "whole and not to chew, crush, or break"; INGREZZA SPRINKLE "may be opened and sprinkled over soft food (do not use milk or drinking water)."
Patient and family teaching
On a VMAT2 inhibitor: report sadness, withdrawal, sleep changes, irritability, restlessness or agitation promptly (on AUSTEDO, report any depression symptoms immediately), and report suicidal thoughts immediately.
Why: XENAZINE: families "remain alert to the emergence of suicidal ideation and to report it immediately to the patient’s physician." AUSTEDO: "to immediately report any symptoms to a healthcare provider."
Go to the nearest emergency room for high fever with stiff muscles and confusion (possible NMS) or, on INGREZZA, for face, lip or throat swelling with trouble breathing; on AUSTEDO or INGREZZA, call the prescriber immediately for fainting, passing out or palpitations.
Why: AUSTEDO and INGREZZA: "consult their physician immediately if they feel faint, lose consciousness, or have heart palpitations" (QT). NMS: "go to the nearest emergency room" (XENAZINE and AUSTEDO Medication Guides); INGREZZA: "report to the emergency room" for NMS or angioedema.
Do not drive or use hazardous machinery until the dose is stable and the effect is known; avoid alcohol and other sedating drugs; tell every prescriber about the medicine before a new drug is started.
Why: XENAZINE: no activities requiring alertness "until they are on a maintenance dose"; "alcohol may potentiate the sedation." AUSTEDO: "inform physicians … before any new drug is taken."
Offer genetic counseling to at-risk relatives; predictive testing is a personal choice, usually at 18 or older, and pre-pregnancy is the best time to discuss risk.
Why: NHS: "It's your choice whether you have the test"; StatPearls: "The optimal time to determine the genetic risk as well as discuss prenatal testing is before pregnancy."
Plan ahead while the patient can still take part: future care, feeding choices such as a PEG, and support groups.
Why: EHDN: "Advanced care planning is essential." NHS suggests talking to others with HD "either at a local support group or online."

How a real nurse thinks

The clinical-judgment loop, worked for a typical presentation — reasoning, not reference.

  1. 1
    Recognize cues

    A possible statement of hopelessness on a VMAT2 inhibitor, coughing at meals, weight loss despite eating, and falls with a head bruise.

  2. 2
    Analyze cues

    Tetrabenazine carries a boxed warning for depression and suicidality in HD, and "Patients with HD who express suicidal ideation should be evaluated immediately." Coughing at meals points to dysphagia and aspiration risk; aspiration pneumonia is the most frequent cause of death. Weight loss can occur "despite normal, or even high calorie intake." Chorea can cause "fractures and head trauma."

  3. 3
    Prioritize

    Safety from suicide first (an immediate evaluation), then airway and aspiration at meals, then nutrition and falls.

  4. 4
    Generate solutions

    Ask him directly about suicidal thoughts, keep him under observation, and notify the provider now for an immediate evaluation; hold the next tetrabenazine dose pending review. Stop the meal, sit him upright and request a swallowing assessment. Ask the dietitian about high-calorie, high-protein supplements. Put fall precautions in place and report the head bruise.

  5. 5
    Take action

    Stays with him, asks about suicidal thoughts, and calls the provider for an immediate evaluation; documents the sister’s report; stops the meal and positions him upright; places a speech-therapy referral and dietitian consult; starts fall precautions.

  6. 6
    Evaluate

    Confirms the suicide evaluation happened and the safety plan is in place; watches the next meals for coughing; tracks weekly weight; counts falls.

Scenario — you’re the nurse

Work each question before revealing the answer. Rationales explain the wrong options too.

Long-term care unit · lunchtime

A 48-year-old man with Huntington’s disease diagnosed 6 years ago. His father had HD. He takes tetrabenazine for chorea. His sister visits daily.

Meal — coughs repeatedly while eating a sandwich; chorea of the arms and trunk
Weight — down 7% over 3 months despite eating most meals
Mood — sister reports he has been withdrawn and said last night ‘there is no point any more’
Mobility — two falls this month; bruise on the forehead
Medicines — tetrabenazine started 3 weeks ago
Q1 Multiple choice
The sister of a patient with Huntington’s disease asks what the chance is that her own child could inherit the gene from her if she has it. What should the nurse say?
  1. A. 25%, because HD is autosomal recessive
  2. B. 50% for each child, because HD is autosomal dominant
  3. C. Only sons can inherit it
  4. D. There is no risk unless both parents have HD
Reveal answer & rationale
Answer: B
NINDS: "When a parent has HD, each child has a 50% chance of inheriting the genetic variant" (B). One altered copy is enough, so it is not recessive (A) and one affected parent is enough (D). HD is not sex-linked (C); anticipation is mainly paternal, but daughters and sons can both inherit it.
Q2 Multiple choice
A patient with HD taking tetrabenazine tells the nurse, ‘My family would be better off without me.’ What is the priority action?
  1. A. Document the statement and recheck at the next shift
  2. B. Ask about suicidal thoughts and arrange an immediate evaluation
  3. C. Give the next tetrabenazine dose to calm him
  4. D. Encourage him to join an HD support group
Reveal answer & rationale
Answer: B
VMAT2 labels: "Patients with HD who express suicidal ideation should be evaluated immediately" (B); suicide is the second cause of death in HD. Waiting (A) delays a life-saving evaluation. Tetrabenazine carries a boxed warning for depression and suicidality and is contraindicated in active suicidality (C). Support groups help later but are not the priority (D).
Q3 Select all that apply
Which findings in a patient with HD should the nurse report to the provider? Select all that apply.
  1. A. Coughing during meals
  2. B. Unintended weight loss over 3 months
  3. C. Two falls this week
  4. D. New withdrawal and insomnia after starting tetrabenazine
  5. E. Mild chorea that does not bother the patient
Reveal answer & rationale
Answer: A, B, C, D
Coughing at meals signals dysphagia and aspiration risk (A); weight loss calls for a dietitian and supplements (B); falls can cause fractures and head trauma (C); XENAZINE: withdrawal and insomnia are reported "promptly to the patient’s physician" (D). EHDN: drug treatment is considered only "if chorea causes the patient distress or discomfort," so mild, untroubling chorea is expected (E).
Q4 Multiple choice
A patient with HD is losing weight despite eating full meals. Which dietary approach is appropriate?
  1. A. Restrict calories to slow weight change
  2. B. High-calorie, high-protein supplements under a dietitian
  3. C. A low-protein diet to reduce movement
  4. D. Clear liquids only
Reveal answer & rationale
Answer: B
EHDN: weight loss can occur "despite normal, or even high calorie intake, due to a significant energy expenditure," and "high-calorie and high-protein food supplements should be prescribed under instruction and monitored by a dietician/nutritionist" (B). Restricting calories (A) or protein (C) worsens weight loss. Clear liquids alone do not meet the high energy needs (D).
Q5 Multiple choice
A patient taking AUSTEDO has worsening dysphagia. The caregiver asks whether she can crush the tablet into applesauce. What should the nurse say?
  1. A. Yes, crushing is fine with food
  2. B. No — AUSTEDO is swallowed whole; ask the prescriber about the swallowing problem
  3. C. Yes, but only with milk
  4. D. Skip the dose on days swallowing is hard
Reveal answer & rationale
Answer: B
AUSTEDO label: swallow "whole and not to chew, crush, or break" (B, A wrong). Milk is not the issue (C). Skipping doses without the prescriber is unsafe (D); the prescriber decides on another option — INGREZZA SPRINKLE is the only VMAT2 product described as opened over soft food.

Common questions

What causes huntington’s disease?
Common causes and risk factors include a parent with hd — autosomal dominant; each child has a 50% chance of inheriting the variant (ninds), cag repeat length — 36 or more in people with hd (ninds); 40 or more almost always causes the disorder (medlineplus genetics), paternal transmission — anticipation (repeat growth, earlier onset) is seen mainly in the paternal line (statpearls), intermediate alleles (27–35 repeats) in a parent — the carrier is unlikely to develop hd, but the repeat may expand into the disease range in children (ninds, statpearls).
If I have the gene, will I definitely get Huntington’s disease?
It depends on the repeat count. NINDS: people with HD may have 36 or more repeats; MedlinePlus Genetics: 36 to 39 repeats "may or may not" cause symptoms, while 40 or more "almost always" do. NHS: "If you have the altered gene, you may have no symptoms for many years, but eventually you will develop Huntington's disease."
Can HD skip a generation or appear with no family history?
MedlinePlus Genetics: "In rare cases, an individual with Huntington's disease does not have a parent with the disorder." StatPearls lists reasons such as "The early death of a parent" or "Late-onset disease in the parent." Parents with 27 to 35 repeats do not develop HD but may pass on an expanded repeat.
Why do chorea medicines need so much monitoring?
VMAT2 inhibitors lower dopamine, which calms chorea, but they carry a boxed warning for depression and suicidality in HD and can cause parkinsonism, sedation, akathisia, swallowing trouble, QT prolongation and NMS (labels). Patients with active suicidality or untreated depression should not take tetrabenazine or deutetrabenazine.
Is there a cure?
No. NHS: "There's currently no cure for Huntington's disease and no treatments that can stop the symptoms getting worse." Treatment aims to manage symptoms and keep the person "comfortable and independent for as long as possible." Research on lowering huntingtin is ongoing (NINDS).
What usually causes death in HD?
StatPearls: "Aspiration pneumonia is the most frequent cause of death, which is followed by suicide." Adults usually live about 15 to 20 years after symptoms begin (MedlinePlus Genetics).

Sources

Reviewed by Hae Suk Lee, RN

Educational summary for nursing students. Scenarios are fictional teaching cases. Always verify against current guidelines and your institution's protocols before acting in practice. Not medical advice.

Bookmark LearnDrugs.com?

Your saved pages are kept in this browser. Add LearnDrugs.com to your browser’s bookmarks to get back to them in one click.

Drag this link to your bookmarks bar: LearnDrugs.com

Or press Ctrl + D to bookmark the page you’re on.